MDSCs expand peripherally in both cancer patients and tumor-bearing mice, at least in part driven by the systemic effects of cancer cell-derived cytokines that influence hematopoiesis in the bone marrow, including IL6 and CSF2 [197]. This evidence concerns the gene IL6 and cancer.